Nucleotide excision repair-deficient human cells in culture exhibit decreased survival after 2-chlorodeoxyadenosine treatment

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3141-3145

  Lawrenzi, James ^a   Bunnell, Amy ^a   Hentosh, Patricia ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

2 Chlorodeoxyadenosine; Anti leukemia drug; DNA repair deficiency; Nucleoside analog; Xeroderma pigmentosum

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CLADRIBINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; EXCISION REPAIR; HUMAN; HUMAN CELL; LYMPHOBLAST; MONOCYTIC LEUKEMIA; PRIORITY JOURNAL; XERODERMA PIGMENTOSUM;

ADENOSINE MONOPHOSPHATE; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CLADRIBINE; DNA REPAIR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTES; TUMOR CELLS, CULTURED; XERODERMA PIGMENTOSUM;

EID: 0041528250     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Saven A: The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol 33: 28-33, 1996.
2. Juliusson G and Liliemark J: 2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia. N Engl J Med 330: 1828-9; discussion 1829-30, 1994.
3. Rondelli D, Lauria F, Zinzani PL, Raspadori D, Ventura MA, Galieni P, Birtolo S, Forconi F, Algeri R and Tura S: 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 58: 46-50, 1997.
4. Robak T: Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 40: 551-64, 2001.
5. Krance RA, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR, Srivastava DK, Mahmoud H, Roberts WM, Tong X, Blakley RL and Ribeiro RC: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19: 2804-11, 2001.
6. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R and Zyroff J: The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93: 1716-20, 1996.
7. Rice GP, Filippi M and Comi G: Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54: 1145-55, 2000.
8. Arner ES: On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk Lymphoma 21: 225-31, 1996.
9. Hentosh P, Koob R and Blakley RL: Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 265: 4033-40, 1990.
10. Yuh SH, Tibudan M and Hentosh P: Analysis of 2-chloro-2'deoxyadenosine incorporation into cellular DNA by quantitative polymerase chain reaction. Anal Biochem 262: 1-8, 1998.
11. Hentosh P and McCastlain JC: Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions. Nucleic Acids Res 19: 3143-8, 1991.
12. Marrot L and Leng M: Chemical probes of the conformation of DNA modified by cis-diamminedichloroplatinum(II). Biochemistry 28: 1454-61, 1989.
13. Wang YH and Griffith J: Effects of bulge composition and flanking sequence on the kinking of DNA by bulged bases. Biochemistry 30: 1358-63, 1991.
14. Sip M, Schwartz A, Vovelle F, Ptak M and Leng M: Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry 31: 2508-13, 1992.
15. Hentosh P, Tibudan M and Grippo P: A human factor that recognizes DNA substituted with 2-chloroadenine, an antileukemic purine analog. Mol Carcinog 13: 245-53, 1995.
16. Feldberg RS: On the substrate specificity of a damage-specific DNA binding protein from human cells. Nucleic Acids Res 8: 1133-43, 1980.
17. Payne A and Chu G: Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. Mutat Res 310: 89-102, 1994.
18. Reardon JT, Nichols AF, Keeney S, Smith CA, Taylor JS, Linn S and Sancar A: Comparative analysis of binding of human damaged DNA-binding protein (XPE) and Escherichia coli damage recognition protein (UvrA) to the major ultraviolet photoproducts: T[c,s]T, T[t,s]T, T[6-4]T, and T[Dewar]T. J Biol Chem 268: 21301-8, 1993.
19. Hwang BJ, Ford JM, Hanawalt PC and Chu G: Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 96: 424-8, 1999.
20. Tang JY, Hwang BJ, Ford JM, Hanawalt PC and Chu G: Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. Mol Cell 5: 737-44, 2000.
21. Chu G and Chang E: Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 87: 3324-8, 1990.
22. Muller MR, Buschfort C, Thomale J, Lensing C, Rajewsky MF and Seeber S: DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia. Clin Cancer Res 3: 2055-61, 1997.
23. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7: 454-61, 2001.
24. Park SY, Lam W and Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62: 459-65, 2002.
25. Pegg AE and Byers TL: Repair of DNA containing 06-alkylguanine, Faseb J 6: 2302-10, 1992.
26. Ali-Osman F, Berger MS, Rairkar A and Stein DE: Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem 54: 11-9, 1994.
27. Koberle B, Masters JR, Hartley JA and Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-6, 1999,
28. Hakimian D, Tallman MS, Kiley C and Peterson L: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82: 1798-802, 1993.
29. Huang MC, Ashmun RA, Avery TL, Kuehl M and Blakley RL: Effects of cytotoxicity of 2-chloro-2'-deoxyadenosine and 2- bromo-2'-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Res 46: 2362-8, 1986.
30. Hentosh P and Grippo P: Template 2-chloro-2'- deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol Pharmacol 45: 955-61, 1994.
31. Nickoloff JA and Hoekstra MF: DNA Damage and Repair. Totowa NJ, Humana Press, 1998.
32. Murray D, Vallee-Lucic L, Rosenberg E and Andersson B: Sensitivity of nucleotide excision repair- deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 22: 21-6,2002.
33. Batty DP and Wood RD: Damage recognition in nucleotide excision repair of DNA. Gene 241: 193-204, 2000.
34. Hermanson-Miller IL and Turchi JJ: Strand-specific binding of RPA and XPA to damaged duplex DNA. Biochemistry 41: 2402-8, 2002.
35. Sugasawa K, Okamoto T, Shimizu Y, Masutani C, Iwai S and Hanaoka F: A multistep damage recognition mechanism for global genomic nucleotide excision repair. Genes Dev 15: 507-21, 2001.
36. Wakasugi M, Shimizu M, Morioka H, Linn S, Nikaido O and Matsunaga T: Damaged DNA-binding protein DDB stimulates the excision of cyclobutane pyrimidine dimers in vitro in concert with XPA and replication protein A. J Biol Chem 276: 15434-40, 2001.
37. Fujiwara Y, Masutani C, Mizukoshi T, Kondo J, Hanaoka F and Iwai S: Characterization of DNA recognition by the human UV-damaged DNA-binding protein. J Biol Chem 274: 20027-33, 1999.
38. Wakasugi M, Kawashima A, Morioka H, Linn S, Sancar A, Mori T, Nikaido O and Matsunaga T: DDB accumulates at DNA damage sites immediately after UV irradiation and directly stimulates nucleotide excision repair. J Biol Chem 277: 1637-40, 2002.